The Role of HMG-I/Y in Uterine Cancer
The Role of HMG-I/Y in Uterine Cancer
批准号:
7143307
负责人:
Linda M S Resar
金额:
$15.53万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-14 至 2008-06-30
关键词:
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Uterine cancer is the most common cancer of the female genital tract and the fourth most frequent cause for cancer death in women in the United States. The only available treatment is hysterectomy; there is no effective adjuvant therapy for this disease after it has spread outside the uterus. Thus, further study has the potential to significantly benefit women's health. Despite the high prevalence of this cancer, the molecular events that lead to neoplastic transformation in the uterus are poorly understood. In addition, there are limited animal models available to study these cancers. To better understand how uterine cancers develop, we are studying genes that contribute to its pathogenesis. Our focus is the HMG-I/Y gene because our preliminary studies suggest that it plays an important role in the development of uterine cancer. The HMG-I/Y gene encodes the HMG-I and - Y chromatin binding proteins, which function in regulating gene expression. Our pilot study shows that HMG-I mRNA and protein are up-regulated in high-grade human uterine cancers, but not low- grade cancers, benign tumors, or normal tissue. We also demonstrated that HMG-I and -Y have oncogenic properties in cultured cells. We recently generated transgenic mice that overexpress HMG-I in lymphoid tissue and all of them develop aggressive lymphoma. The transgene is also overexpressed in the uterus and all female mice develop uterine tumors with pathology resembling human uterine adenosarcoma. Thus, we hypothesize that HMG-I is an oncogene important in the pathogenesis of human uterine cancer. Our overall goal is to define the role of HMG-I in uterine cancer and begin to explore the mechanisms involved in transformation using unique reagents developed in my laboratory. Our Specific Aims are: 1.) Determine if HMG-I/Y can serve as a diagnostic marker for more aggressive uterine cancer. 2.) Determine if HMG-I/Y is necessary for transformation in uterine cancer cells. 3.) Begin to define the molecular pathways involved in H/WG-/-mediated transformation in uterine cancer using gene expression profile analysis. Results from these studies will enhance our understanding of uterine cancer and should ultimately lead to the development of better therapy. Relevance: Uterine cancer is a common and often incurable cancer that affects women worldwide. There is no effective therapy for this cancer after it has spread outside the uterus. Thus, research is urgently needed to determine how these cancers develop in order to design better therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
High Mobility Group A1 Chromatin Regulators in Colon Carcinogenesis
-
批准号:9750308
-
项目类别:
-
资助金额:$38.37万
-
财政年份:2018
-
负责人:Linda M S Resar
-
依托单位:
High Mobility Group A1 Chromatin Regulators in Colon Carcinogenesis
-
批准号:10197847
-
项目类别:
-
资助金额:$35.68万
-
财政年份:2018
-
负责人:Linda M S Resar
-
依托单位:
High Mobility Group A1 Chromatin Regulators in Colon Carcinogenesis
-
批准号:10599596
-
项目类别:
-
资助金额:$11.39万
-
财政年份:2018
-
负责人:Linda M S Resar
-
依托单位:
The HMGA1 Chromatin Regulator in Hematopoietic Stem Cells with Aging
-
批准号:9391829
-
项目类别:
-
资助金额:$29.43万
-
财政年份:2017
-
负责人:Linda M S Resar
-
依托单位:
Developing a Screen for Novel Therapies with Reprogrammed Pancreatic Cancer Cells
-
批准号:8989083
-
项目类别:
-
资助金额:$8.1万
-
财政年份:2015
-
负责人:Linda M S Resar
-
依托单位:
Developing a Screen for Novel Therapies with Reprogrammed Pancreatic Cancer Cells
-
批准号:8808137
-
项目类别:
-
资助金额:$8.1万
-
财政年份:2015
-
负责人:Linda M S Resar
-
依托单位:
Developing Nanotechnology to Target HMGA1 in Pancreatic Cancer
-
批准号:8883440
-
项目类别:
-
资助金额:$8.1万
-
财政年份:2014
-
负责人:Linda M S Resar
-
依托单位:
Developing Nanotechnology to Target HMGA1 in Pancreatic Cancer
-
批准号:8771691
-
项目类别:
-
资助金额:$7.05万
-
财政年份:2014
-
负责人:Linda M S Resar
-
依托单位:
Targeting the let-7-HMGA2 Network in Metastatic Progression in Pancreatic Cancer
-
批准号:8508216
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2012
-
负责人:Linda M S Resar
-
依托单位:
Targeting the let-7-HMGA2 Network in Metastatic Progression in Pancreatic Cancer
-
批准号:8385138
-
项目类别:
-
资助金额:$8.1万
-
财政年份:2012
-
负责人:Linda M S Resar
-
依托单位:
HMGA1 in Tumor Progression in Breast Cancer
-
批准号:8061682
-
项目类别:
-
资助金额:$17.3万
-
财政年份:2010
-
负责人:Linda M S Resar
-
依托单位:
HMGA1 in Tumor Progression in Breast Cancer
-
批准号:7876146
-
项目类别:
-
资助金额:$21.4万
-
财政年份:2010
-
负责人:Linda M S Resar
-
依托单位:
Targeting HMGA1 in Pancreatic Tumor Progression
-
批准号:7643594
-
项目类别:
-
资助金额:$8.2万
-
财政年份:2009
-
负责人:Linda M S Resar
-
依托单位:
Targeting HMGA1 in Pancreatic Tumor Progression
-
批准号:7769501
-
项目类别:
-
资助金额:$8.2万
-
财政年份:2009
-
负责人:Linda M S Resar
-
依托单位:
The Role of HMG-I/Y in Uterine Cancer
-
批准号:7267961
-
项目类别:
-
资助金额:$18.15万
-
财政年份:2006
-
负责人:Linda M S Resar
-
依托单位:
Mechanisms of Neoplastic Transformation by HMG-I/Y
-
批准号:6613196
-
项目类别:
-
资助金额:$29.1万
-
财政年份:2003
-
负责人:Linda M S Resar
-
依托单位:
Mechanisms of Neoplastic Transformation by HMG-I/Y
-
批准号:6949567
-
项目类别:
-
资助金额:$29.1万
-
财政年份:2003
-
负责人:Linda M S Resar
-
依托单位:
Mechanisms of Neoplastic Transformation by HMG-I/Y
-
批准号:7093550
-
项目类别:
-
资助金额:$28.42万
-
财政年份:2003
-
负责人:Linda M S Resar
-
依托单位:
Mechanisms of Neoplastic Transformation by HMG-I/Y
-
批准号:6767574
-
项目类别:
-
资助金额:$29.1万
-
财政年份:2003
-
负责人:Linda M S Resar
-
依托单位:
HMG-1/Y AND NEOPLASTIC TRANSFORMATION
-
批准号:6513142
-
项目类别:
-
资助金额:$10.59万
-
财政年份:1998
-
负责人:Linda M S Resar
-
依托单位:
国内基金
海外基金
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
-
批准号:82372275
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘耀宝
-
依托单位:
Sestrin2抑制内质网应激对早产儿视网膜病变的调控作用及其机制研究
-
批准号:82371070
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵培泉
-
依托单位: